SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2017 / Cilt: 15 - Sayı: 3

Tenoxicam-Induced Fixed Drug Eruption Confirmed by Skin Patch Test

Deri Yama Testi ile Doğrulanan Tenoksikamın Neden Olduğu Fiks İlaç Erüpsiyonu

İNSU YILMAZ
NURİ TUTAR
Sevim YENİGÜN
Zuhal ŞİMŞEK ÖZER
İNCİ GÜLMEZ
Pages
62–64
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here we described a case of bullous fixed drug eruption due to tenoxicam and we demonstrated the contribution of skin patch tests to the FDE diagnosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fixed drug eruption (FDE) with oxicams is very rare.
📊
Key Findings & Data:Our case was a 63-year-old woman who had developed itching and erythematous lesions 3-5 cm in size localized on her hands and elbows 3-4 hours after the intake of tenoxicam and ranitidine.
💡
Conclusion & Impact:Here we described a case of bullous fixed drug eruption due to tenoxicam and we demonstrated the contribution of skin patch tests to the FDE diagnosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fixed drug eruption (FDE) with oxicams is very rare. FDE due to tenoxicam has been reported in several case reports. Skin patch test with the suspected or responsible drug is applied on sites of previous lesions developing with FDE. Recently, the test has been used quite often for diagnosis of FDE although results are variable. Our case was a 63-year-old woman who had developed itching and erythematous lesions 3-5 cm in size localized on her hands and elbows 3-4 hours after the intake of tenoxicam and ranitidine. The lesion became vesiculobullous a few days later. After two weeks, it resolved with hyperpigmentation. The diagnosis of tenoxicaminduced FDE was confirmed after applying patch and provocation tests. Here we described a case of bullous fixed drug eruption due to tenoxicam and we demonstrated the contribution of skin patch tests to the FDE diagnosis.

Özet

Oksikamlar ile fiks ilaç erüpsiyonu (FİE) oldukça nadirdir. Tenoksikam ile FİE ise birkaç olgu raporu şeklinde bildirilmiştir. FİE gelişen rezidüel lezyon üzerine, şüpheli ya da sorumlu ilaç ile deri yama testi uygulanması, sonuçları değişken olmakla birlikte FİE tanısı için son dönemlerde oldukça sık kullanılmaya başlanmıştır. Altmış üç yaşındaki kadın olgumuzda, ranitidin ve tenoksikam kullanımından 3-4 saat sonra ellerinde ve dirseklerinde 3-5 cm çapında, kaşıntılı ve eritemli lezyonlar gelişmiş. Birkaç gün sonra aynı bölgeler vezikülobüllöz lezyonlar halini alarak, iki hafta sonra hiperpigmente alan bırakarak iyileşmiştir. Hastamızda deri yama ve provokasyon testleri sonrası tenoksikam ile FİE tanısı konfirme edilmiştir. Biz burada, tenoksikam ile nadir görülen büllöz FİE olgusunu ve bu olgularda deri yama testlerinin tanıya katkısını göstermeyi amaçladık.

🔖

Cite This Article

YILMAZ, İ., TUTAR, N., YENİGÜN, S., ÖZER, Z. Ş., GÜLMEZ, İ. (2017). Tenoxicam-Induced Fixed Drug Eruption Confirmed by Skin Patch Test. Astım Allerji İmmünoloji, Cilt: 15 - Sayı: 3, 62–64. https://ajindex.com/articles/147399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rasi A, Khatami A. Unilateral non-pigmenting fixed drug eruption associated with cotrimoxazole. Dermatol Online J 2006;12:12
  2. Tavallaee M, Rad MM. Fixed drug eruption resulting from fluconazole use: A case report. J Med Case Rep 2009;3:7368
  3. Montoro J, Díaz M, Genís C, Lozano A, Bertomeu F. Nonpigmenting cutaneous-mucosal fixed drug eruption due to piroxicam. Allergol Immunopathol 2003;31:53-5
  4. Ordoqui E, De Barrio M, Rodríguez VM, Herrero T, Gil PJ, Baeza ML. Cross-sensitivity among oxicams in piroxicamcaused fixed drug eruption: Two case reports. Allergy 1995;50:741-4
  5. Ozkaya-Bayazit E. Independent lesions of fixed drug eruption caused by trimethoprim-sulfamethoxazole and tenoxicam in the same patient: A rare case of polysensitivity. J Am Acad Dermatol 2004;51:S102-4
  6. Barbaud A, Gonc¸alo M, Bruynzeel D, Bircher A; European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321-8
  7. Jelvehgari M, Azimi H, Montazam H. Prevalence of cutaneous drug eruption in hospitalized patients: A report from Sina Hospital of Tabriz. Iran J Dermatol 2009;12:16-9
  8. Brocq L. Eruption érythématopigmenteé fixe due à l'antipyrine. Ann Dermat Syph 1894;5:308-13
  9. Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 2002;161:1337-47
  10. Shiohara T, Mizukawa Y, Teraki Y. Patophysiology of fixed drug eruption: The role of skin-resident T-cells. Curr Opin Allergy Clin Immunol 2002;2:317-23
  11. Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol 2003;112:609-15
  12. Ewald R, Roos U. Therapeutic experiences with tenoxicam. Results of an observational study of 18,976 patients. Fortschr Med 1990;108:682-6
  13. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998:139:49-58
  14. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005:209:209-16
  15. Wolkenstein P, Chosidow O, Fléchet ML, Robbiola O, Paul M, Dumé L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnso